AstraZeneca’s Olaparib Clears FDA For Later Therapy Line In Ovarian Cancer

AstraZeneca’s Lynparza was rejected as a maintenance therapy after second-line treatment by an FDA advisory committee, but landed accelerated approval for heavily pretreated relapsed patients, based on data not considered in the initial advisory committee review.